Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
DRUG

Interferon Beta-1a

Trial Locations (20)

2006

Institute of Clinical Neurosciences, Sydney

2170

Liverpool Hospital, Liverpool

3050

Royal Melbourne Hospital, Parkville

3065

St. Vincent's Hospital, Fitzroy

10022

Weill Medical College of Cornell University, New York

27607

Raleigh Neurology Associates, Raleigh

32209

University of Florida, Jacksonville, Jacksonville

33136

University of Miami, Miami

55455

University of Minnesota, Minneapolis

66160

University of Kansas, Kansas City

70112

Louisiana State University, New Orleans

84132

University of Utah, Salt Lake City

85006

Phoenix Neurological Associates, Ltd., Phoenix

85258

Neuromuscular Research Center, Scottsdale

02114

Harvard University/MGH, Boston

02135

Tufts University/ St. Elizabeths, Boston

75390-8897

University of Texas Southwestern, Dallas

N6A 5A5

London Health Sciences Center, London

H3A 2B4

Montreal Neurological Hospital, Montreal

SE1 1UL

Guy's Hospital/Dept. of Neuroimmunology, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00099489 - Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Biotech Hunter | Biotech Hunter